Financial News

Auspex Pharmaceuticals reports positive trial data

Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) reported positive results from a Phase 3 clinical trial of SD-809 for treating chorea associated with Huntington's disease sending the stock price soaring $25.05 to close at $50.14.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback